The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
O'ShaughnessyJ., MilesD., VukeljaS.. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol.2002; 20: 2812–2823.
PuglisiF., ScaloneF., MinisiniA.M.. A phase II study of capecitabine and weekly docetaxel combination chemotherapy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol.2005 (abstract 804). Available at: http://www.asco.org. Accessed February 9, 2007.
4.
ChanS., RomieuG., HuoberJ.. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Proc Am Soc Clin Oncol.2005 (abstract 581). Available at: http://www.asco.org. Accessed February 9, 2007.
5.
LebowitzP.F., Eng-WongJ., SwainS.M.. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res.2004; 10: 6764–6769.
6.
MackeyJ.R., TonkinK.S., KoskiS.L.. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer.2004; 5: 287–292.
7.
LlorcaC., MayordomoJ., AdroverE.. Activity and safety of biweekly docetaxel plus capecitabine as first-line treatment of patients with metastatic breast cancer. Proc Am Soc Clin Oncol.2004 (abstract 788). Available at: http://www.asco.org. Accessed February 9, 2007.
8.
LimH-S, LeeH.G., ChunJ.H., LeeJ.J., LeeJ.S., RoJ.A phase II study of docetaxel (T) and capecitabine (X) combination chemotherapy as first-line chemotherapy for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol.2005 (abstract 889). Available at: http://www.asco.org. Accessed February 9, 2007.
9.
BelletM., MuñozM., SuárezM.. Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile. Early results. Proc Am Soc Clin Oncol.2005 (abstract 735). Available at: http://www.asco.org. Accessed February 9, 2007.
10.
ParkY.H., RyooB.Y., ChoiS.J., KimH.T.A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer.2004; 90: 1329–1333.
11.
KimJ.G., SohnS.K., KimD.H.. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology.2005; 68: 190–195.
12.
Thuss-PatienceP.C., KretzschmarA., LoewA.. Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study. Proc Am Soc Clin Oncol.2005 (abstract 4224). Available at: http://www.asco.org. Accessed February 9, 2007.
13.
CatalanoG., OrdituraM., DiademaM.R., AurilioG., CiardielloF., de VitaF.Phase II study of weekly docetaxel and capecitabine in patients with metastatic gastric cancer (GC). Proc Am Soc Clin Oncol.2005 (abstract 4207). Available at: http://www.asco.org. Accessed February 9, 2007.
14.
ChunJ.H., KimH.K., LeeJ.S.. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol.2005; 28: 188–194.
15.
LorenzenS., DuysterJ., LerschC.. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer.2005; 92: 2129–2133.
16.
VaishampayanU.N., HeilbrunL., EliasonJ., PontesE., PowellI., FormanJ.Docetaxel and capecitabine in metastatic androgen independent prostate cancer (AIPC): phase II trial to detect clinical efficacy of a synergistic combination. Proc Am Soc Clin Oncol.2005 (abstract 4703). Available at: http://www.asco.org. Accessed February 9, 2007.
17.
FriedmanJ.D., VaishampayanU., MontieJ.. Neoadjuvant docetaxel and capecitabine in patients with high risk/locally advanced prostate cancer: Preliminary results of a phase II study. Proc Am Soc Clin Oncol.2005 (abstract 4742). Available at: http://www.asco.org. Accessed February 9, 2007.
18.
Kindwall-KellerT., OttersonG.A., YoungD.. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res.2005; 11: 1870–1876.
19.
HanJ.Y., LeeD.H., KimH.Y.. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer.2003; 98: 1918–1924.
20.
RamanathanR.K., RamalingamS., EgorinM.J.. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol.2005; 55: 354–360.
21.
National Cancer Comprehensive Network.NCCN Clinical Practice Guidelines – Invasive Breast Cancer. V.2.2006. Available at: http://www.nccn.org. Accessed February 9, 2007.
22.
VermaS., IlersichA.L.Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pre-treated metastatic breast cancer. Oncologist.2003; 8: 232–240.
23.
CohenM.R., SmetzerJ.Preparing for a damaging medication error. ISMP Medication Safety Alert!1999; 4: 14.
24.
CohenM.R., SmetzerJ.Preparing for a damaging medication error. ISMP Med Safety Alert!2001; 6: 3.
25.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–109.
26.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. Available at: http://www.nccn.org/. Accessed February 9, 2007.
27.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24: 2932–2947.
28.
Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2005. Available at: http://www.mascc.org/. Accessed February 9, 2007.
29.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23: 1289–1294.
30.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
31.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9: 381–385.
32.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85: 1099–1101.
33.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119: 350–354.
34.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2: 177–183.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24: 767–779.
37.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24: 3187–3205.
38.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. v.1.2006. Available at: http://www.nccn.org/. Accessed February 9, 2007.
39.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
BrunoR., HilleD., RivaA.. Populations pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol.1998; 16: 187–196.
42.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
43.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
